The FDA has approved the subcutaneously injected monoclonal antibody dupilumab (Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of patients ≥12 years old with moderate to severe asthma with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Dupilumab was approved earlier to treat adults with moderate to severe atopic dermatitis inadequately controlled with topical therapies.1

MECHANISM OF ACTION — Dupilumab, a fully human IgG4 monoclonal antibody, binds to the interleukin (IL)-4 receptor alpha subunit shared by IL-4 and IL-13 receptors, inhibiting the signaling of these cytokines, which are thought to be the drivers of inflammation in atopic dermatitis, asthma, and possibly other allergic diseases.2

MONOCLONAL ANTIBODIES FOR ASTHMA — Asthma patients who do not respond ... more      

Would you like to read the rest of this article?  Gain access below.